Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

[{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Efavirenz","moa":"||RNase H","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Efavirenz / emtricitabine / tenofovir disoproxil

Efavirenz / emtricitabine / tenofovir disoproxil
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check COS database
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Efavirenz / emtricitabine / tenofovir disoproxil

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

51 API Suppliers, 28 USDMF, 13 EU WC, 2 KDMF, 22 NDC API, 20 Listed Suppliers, $ API Reference Price

51 API Suppliers
28 USDMF
13 EU WC
2 KDMF
22 NDC API
20 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

197 FDF Dossiers, 59 FDA Orange Book, 40 Europe, 11 Canada, 67 South Africa, 20 Listed Dossiers

197 FDF Dossiers
59 FDA Orange Book
40 Europe
11 Canada
67 South Africa
20 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 400MG;300MG;300MG, CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 600MG, TABLET;ORAL - 600MG;200MG;300MG

TABLET;ORAL - 400MG;300MG;300MG
CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 600MG
TABLET;ORAL - 600MG;200MG;300MG

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 10 DKSH, 4 Faran Shimi Pharmaceutical, 5 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 14 BASF, 10 Corel Pharma Chem, 6 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 7 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 31 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 12 Roquette, 7 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 12 Sigachi Industries, 2 The Dow Chemical Company, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

52 Coating Systems & Additives, 45 Fillers, Diluents & Binders, 28 Controlled & Modified Release, 24 Disintegrants & Superdisintegrants, 22 Thickeners and Stabilizers, 17 Granulation, 16 Lubricants & Glidants, 14 Direct Compression, 10 Topical, 9 Empty Capsules, 8 Film Formers & Plasticizers, 7 Co-Processed Excipients, 6 Taste Masking, 5 Solubilizers, 5 Rheology Modifiers, 5 API Stability Enhancers, 5 Coloring Agents, 4 Emulsifying Agents, 4 Vegetarian Capsules, 3 Chewable & Orodispersible Aids, 3 Parenteral, 1 Surfactant & Foaming Agents

52 Coating Systems & Additives
45 Fillers, Diluents & Binders
28 Controlled & Modified Release
24 Disintegrants & Superdisintegrants
22 Thickeners and Stabilizers
17 Granulation
16 Lubricants & Glidants
14 Direct Compression
10 Topical
9 Empty Capsules
8 Film Formers & Plasticizers
7 Co-Processed Excipients
6 Taste Masking
5 Solubilizers
5 Rheology Modifiers
5 API Stability Enhancers
5 Coloring Agents
4 Emulsifying Agents
4 Vegetarian Capsules
3 Chewable & Orodispersible Aids
3 Parenteral
1 Surfactant & Foaming Agents

DIGITAL CONTENT

55 News #PharmaBuzz

55 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 24 Regulatory FDF Prices, 15 Annual Reports

3 US Medicaid Prescriptions
24 Regulatory FDF Prices
15 Annual Reports

MARKET PLACE

8 APIs, 5 FDF Dossiers

8 APIs
5 FDF Dossiers

PATENTS & EXCLUSIVITIES

5 US Patents, 10 Health Canada Patents

5 US Patents
10 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 USP, 5 Others

5 USP
5 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

Xls

Filters

×

FILTER:

filter

Company Name

1
ALL
1
Strides Pharma Science

filter

Year

1
ALL
1
2023

filter

DEALS // DEV.

1
ALL
1
Developments

filter

Country

1
ALL
1
INDIA

filter

Sponsor

1
ALL
1
Inapplicable

filter

Therapeutic Area

1
ALL
1
Infections and Infectious Diseases

filter

Study Phase

1
ALL
1
Approved FDF

filter

Deal Type

1
ALL
1
Inapplicable

filter

Product Type

1
ALL
1
Other Small Molecule

filter

Dosage Form

1
ALL
1
Oral Tablet, Film Coated

filter

Lead Product

1
ALL
1
Efavirenz

filter

Target

1
ALL
1
RNase H

All Developments

Therapeutic Area by Lead Product

Sample Tooltip

Study Phase by Lead Product

Sample Tooltip

Company by Lead Product

Sample Tooltip

Top Deals by Deal Size (USD bn)

Sample Tooltip

Reset All

01

Strides Pharma Science

India

CPhI WW Frankfurt

Booth # 9.1F6 & 9.1G41

Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.

Lead Product(s) : Efavirenz,Emtricitabine,Tenofovir Disproxil Fumurate

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Strides Receives USFDA Approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate Tablets

Details : Efavirenz/ Emtricitabine/tenofovir disoproxil fumarate) tablets a combination of 2 nucleoside analog HIV-1 reverse transcriptase inhibitors and 1 non-nucleoside HIV-1 reverse transcriptase inhibitor, for the treatment of HIV-1 infection.

Product Name : Atripla-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

April 10, 2023

Lead Product(s) : Efavirenz,Emtricitabine,Tenofovir Disproxil Fumurate

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Strides Pharma Science

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

Privacy policy
Terms and conditions
Disclaimers
Ask Us!